Here are the 10-Q quarterly reports from Intellia Therapeutics, Inc (NTLA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NTLA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTLA filings page.
Intellia Therapeutics, Inc. (NTLA) reported third-quarter collaboration revenue of $7.2 million, down from $13.8 million a year earlier, and a net loss of $127.5 million, versus $101.3 million. Nine-month revenue was $29.9 million versus $44.7 million; operating cash used was $285.9 million versus $325.5 million.
The FDA accepted lonvo-z’s BLA and granted Priority Review, with a PDUFA target action date of March 10, 2027. In Phase 3 HAELO, a one-time infusion reduced HAE attacks 87% versus placebo during weeks 5–28; 62% of lonvo-z patients were entirely attack-free and therapy-free versus 11% on placebo. Intellia’s initial draw was $75 million under a five-year senior secured facility of up to $400 million; potential additional term loans are tied to FDA approval, revenue or equity-fundraising milestones.
The FDA lifted clinical holds on both nex-z Phase 3 trials in 2026. An analysis of more than 600 patient samples found the highest observed liver transaminase elevations in patients carrying one specific HLA allele; Intellia said it would provide genotyping results for enrolled and screening patients while engaging with the FDA.
Intellia Therapeutics (NTLA) reported Q3 2025 results showing collaboration revenue of $13,782 and a net loss of $101,324. Operating expenses fell year over year as research and development declined to $94,747 from $123,380, while general and administrative was essentially flat at $30,512. Other income, net, was $10,153, driven primarily by interest income.
Liquidity remained sizable with cash and cash equivalents of $193,389 and marketable securities of $476,469 as of September 30, 2025. Year to date, the company raised $128,175 through at-the-market share sales and ended the quarter with 115,787,285 shares outstanding; 115,829,926 shares were outstanding as of October 31, 2025. Stockholders’ equity was $748,422.
Strategic updates included a January workforce reduction of about 27% with $6,500 in restructuring charges. The company amended and partially terminated facility leases, paying $34,000 in February and $30,000 in April 2025, with $14,000 due in January 2026, and recorded $40,500 of prepaid rent tied to a new Tech Square lease. Collaboration activity included a $1,800 milestone recognized under the Regeneron agreements, termination of the ReCode agreement in September 2025, and termination of the SparingVision collaboration in October 2025 with the return of 50% of its Series A2 shares.